Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-11-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 16.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 112 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 23.3% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Sponsor's past trials: 1155 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tumorssolidcarboplatincellsmall
  Phrases that lowered it: first dosevaccineparticipantsdose ofsystemic
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 94.4% (raises risk) · Drug's FDA history
• Number of arms: 7 (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 17676 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants NCT04939701 · started 2021 · scored riskier than 62% of active trials terminated
• MK-3475 as Maintenance Therapy in Extensive Stage SCLC NCT02359019 · started 2015 · scored riskier than 94% of active trials completed
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) NCT02578680 · started 2016 · scored riskier than 40% of active trials completed
• A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors NCT04452214 · started 2020 · scored riskier than 79% of active trials completed
• A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies NCT04244552 · started 2020 · scored riskier than 25% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.